Intravitreal dexamethasone implant for the treatment of refractory macular edema in retinal vascular diseases : Results of the KKESH International Collaborative Retina study group

Retina

Volumn 36, Issue 1, 2016, Pages 131-136

  Alshahrani, Saeed T ^a,b   Dolz Marco, Rosa ^c   Gallego Pinazo, Roberto ^c   Diaz Llopis, Manuel ^c   Arevalo, J Fernando ^a,d  

^a KING KHALED EYE SPECIALIST HOSPITAL   (Saudi Arabia)

^b KING FAHAD SPECIALIST HOSPITAL   (Saudi Arabia)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DEX implant; Macular edema; Ozurdex; Retina

Indexed keywords

DEXAMETHASONE; DRUG IMPLANT; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CATARACT; CENTRAL MACULAR THICKNESS; CENTRAL RETINA VEIN OCCLUSION; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG IMPLANT; DRUG SAFETY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MACULAR EDEMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; RETROSPECTIVE STUDY; SIDE EFFECT; VERY ELDERLY; VISUAL ACUITY; COMPLICATION; DIABETIC RETINOPATHY; INTRAVITREAL DRUG ADMINISTRATION; OCULOPLETHYSMOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA; RETINAL VEIN OCCLUSION;

ADULT; AGED; AGED, 80 AND OVER; DEXAMETHASONE; DIABETIC RETINOPATHY; DRUG IMPLANTS; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETINA; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TONOMETRY, OCULAR; VISUAL ACUITY;

EID: 84952890849     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000616     Document Type: Article

References (22)

1. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-1806.
2. Glacet-Bernard A, Zourdani A, Milhoub M, et al. Effect of isovolemic hemodilution in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2001;239:909-914.
3. Hansen LL, Wiek J, Wiederholt M. A randomised prospective study of treatment of non-ischemic central retinal vein occlusion by isovolaemic hemodilution. Br J Ophthalmol 1989;73: 895-899.
4. Wolf S, Arend O, Bertram B, et al. Hemodilution therapy in central retinal vein occlusion. One-year results of a prospective randomized study. Graefes Arch Clin Exp Ophthalmol 1994; 232:33-39.
5. Kalogeropoulos C, Donati G, Pizzolato GP, et al. Morphology of early retinal lesions after experimental venous occlusion. Klin Monatsbl Augenheilkd 1996;208:375-376.
6. Martindale: The Complete Drug Reference. Pharmaceutical Press. Available at: www.medicinescomplete.com. Accessed August 26, 2010.
7. National Institute for Health and Clinical Excellence. Draft scope (pre-referral) for dexamethasone intravitreal implant for the treatment of macular oedema caused by retinal vein occlusion. 2010. Accessed January 26, 2010.
8. Kang BS, Chung EY, Yun YP, et al. Inhibitory effects of antiinflammatory drugs on interleukin-6 bioactivity. Biol Pharm Bull 2001;24:701-703.
9. Umland SP, Nahrebne DK, Razac S, et al. The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon-gamma production by cultured primary CD4+ T cells. J Allergy Clin Immunol 1997;100:511-519.
10. Floman N, Zor U. Mechanism of steroid action in ocular inflammation: Inhibition of prostaglandin production. Invest Ophthalmol Vis Sci 1977;16:69-73.
11. Summary of product characteristics. Ozurdex. (Allergan ltd). Available at: www.medicines.org.uk/emc. Accessed September 26, 2010.
12. Commercial information available online via. Available at: www.ozurdex.com/HCP/Default.aspx. Accessed September 26, 2010.
13. Anon. Advance notification document: dexamethasone 700 (xg intravitreal implant in applicator (OZURDEX™) for retinal vein occlusion. Allergan, 2009.
14. Haller JA, Bandello F, Belfort R Jr, et al; Ozurdex GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117: 1134-1146.
15. Haller JA, Kuppermann BD, Blumenkranz MS, et al; Dexa-methasone DDS Phase II Study Group. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010; 128:289-296.
16. Boyer DS, Faber D, Gupta S, et al; Ozurdex Champlain Study Group. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011;31:915-923.
17. Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacoki-netics and pharmacodynamics of a sustained-release dexameth-asone intravitreal implant. Invest Ophthalmol Vis Sci 2011;52: 80-86.
18. Dutra Medeiros M, Postorino M, Navarro R, et al. Dexameth-asone intravitreal implant for treatment of patients with persistent diabetic macular edema. Ophthalmologica 2014; 231:141-146.
19. Zucchiatti I, Lattanzio R, Querques G, et al. Intravitreal dexa-methasone implant in patients with persistent diabetic macular edema. Ophthalmologica 2012;228:117-122.
20. Ferrini W, Ambresin A Intravitreal dexamethasone implant for the treatment of macular edema after retinal vein occlusion in a clinical setting. Klin Monbl Augenheilkd 2013;230: 423-426.
21. Matonti F, Meyer F, Guigou S, et al. Ozurdex in the management of the macular edema following retinal vein occlusion in clinical practice. Acta Ophthalmol 2013;91:e584-586.
22. Boyer DS, Yoon YH, Belfort R Jr., et al; Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014;121: 1904-1914.